GlaxoSmithKline
NEWS
Topline data from Merck KGaA’s Phase II INTR@PID BTC 047 study show bintrafusp alfa has single-agent efficacy and safety in the second-line treatment of locally advanced or metastatic biliary tract cancer in patients who have either failed or are intolerant to first-line platinum-based chemotherapy.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
Genentech reported its rheumatoid arthritis drug Actemra failed to hit its primary endpoint in a COVID-19 trial, while Vir and GlaxoSmithKline’s antibody against COVID-19 demonstrated 85% efficacy.
GlaxoSmithKline failed to hit a key internal profit goal in 2020, due in large part to the impact of the COVID-19 pandemic. As a result, Chief Executive Officer Emma Walmsley took a nearly $2 million hit to her annual compensation.
In a list of the most innovative vaccine makers in 2021, Fast Company has outlined 10 biotech companies that continue to revolutionize the drug-discovery landscape.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
The study of VIR-7831, which is a dual-action SARS-CoV-2 monoclonal antibody, was recommended to be closed to enrollment by an independent data monitoring board, stating that “there were no reported safety signals, sensitivity analyses of the available data raised concerns about the magnitude of potential benefit.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 23, 2021.
JOBS
IN THE PRESS